The Experts below are selected from a list of 162 Experts worldwide ranked by ideXlab platform
Walter Rhomberg - One of the best experts on this subject based on the ideXlab platform.
-
Razoxane and dexRazoxane
2017Co-Authors: Kurt Hellmann, Walter RhombergAbstract:Razoxane and dexRazoxane : , Razoxane and dexRazoxane : , کتابخانه دیجیتالی دانشگاه علوم پزشکی ارومیه
-
comprar Razoxane and dexRazoxane two multifunctional agents rhomberg walter 9789048191673 springer
2011Co-Authors: Walter Rhomberg, Kurt HellmannAbstract:Tienda online donde Comprar Razoxane and DexRazoxane - Two Multifunctional Agents al precio 151,19 € de Rhomberg, Walter | Hellmann, Kurt, tienda de Libros de Medicina, Libros de Cardiologia - Cardiologia general
-
Comprar Razoxane and DexRazoxane - Two Multifunctional Agents | Rhomberg, Walter | 9789048191673 | Springer
2011Co-Authors: Walter Rhomberg, Kurt HellmannAbstract:Tienda online donde Comprar Razoxane and DexRazoxane - Two Multifunctional Agents al precio 151,19 € de Rhomberg, Walter | Hellmann, Kurt, tienda de Libros de Medicina, Libros de Cardiologia - Cardiologia general
-
treatment of vascular soft tissue sarcomas with Razoxane vindesine and radiation
International Journal of Radiation Oncology Biology Physics, 2009Co-Authors: Walter Rhomberg, Helmut Eiter, Anna Wink, Boris Pokrajac, B Pakisch, Angela Ginestet, Peter Lukas, ACHIM HACKL, Richard PotterAbstract:Purpose In previous studies, Razoxane and vindesine together with radiotherapy was proved to be effective in soft tissue sarcomas (STS). Because Razoxane leads to a redifferentiation of pathological tumor blood vessels, it was of particular interest to study the influence of this drug combination in vascular soft tissue sarcomas. Methods and Materials This open multicenter Phase II study was performed by the Austrian Society of Radiooncology. Among 13 evaluable patients (10 angiosarcomas and 3 hemangio-pericytomas), 9 had unresectable measurable disease, 3 showed microscopic residuals, and 1 had a resection with clear margins. They received a basic treatment with Razoxane and vindesine supported by radiation therapy. Outcome measures were objective response rates, survival time, and the incidence of distant metastases. Results In nine patients with measurable vascular soft tissue sarcomas (eight angiosarcomas and one hemangiopericytoma), 6 complete remissions, 2 partial remissions, and 1 minor remission were achieved, corresponding to a major response rate of 89%. A maintenance therapy with Razoxane and vindesine of 1 year or longer led to a suppression of distant metastases. The median survival time from the start of the treatment is 23+ months (range, 3–120+) for 12 patients with macroscopic and microscopic residual disease. The progression-free survival at 6 months was 75%. The combined treatment was associated with a low general toxicity, but attention must be given to increased normal tissue reactions. Conclusions This trimodal treatment leads to excellent response rates, and it suppresses distant metastases when given as maintenance therapy.
-
Combined vindesine and Razoxane shows antimetastatic activity in advanced soft tissue sarcomas
Clinical & Experimental Metastasis, 2008Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Schmid, Christoph H. SaelyAbstract:Background Razoxane and vindesine were shown to suppress distant metastasis in animal systems. Both drugs affect main steps of the metastatic cascade. Therefore, a pilot study was performed to study the influence of these drugs on the dynamics of metastasis in advanced soft tissue sarcomas (STS). This study was now updated. Methods Twenty-three patients with unresectable ( n = 7) and oligometastatic STS ( n = 16) received a basic treatment with Razoxane and vindesine supported by radiotherapy and occasionally by surgery. Long-term treatment was intended in patients with metastatic disease. The cumulative number of new metastases after 6 and 9 months were determined. Thirty-six patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomized, retrospective controls. The prognostic parameters of the groups were comparable. Results In patients receiving Razoxane and vindesine, the median number of new metastases after 6 months was 0 (range, 0–40) and after 9 months likewise 0 (0–70). The corresponding numbers in the control group were 4.5 (range, 0–40) and 9 (0–>100) ( P
Helmut Eiter - One of the best experts on this subject based on the ideXlab platform.
-
treatment of vascular soft tissue sarcomas with Razoxane vindesine and radiation
International Journal of Radiation Oncology Biology Physics, 2009Co-Authors: Walter Rhomberg, Helmut Eiter, Anna Wink, Boris Pokrajac, B Pakisch, Angela Ginestet, Peter Lukas, ACHIM HACKL, Richard PotterAbstract:Purpose In previous studies, Razoxane and vindesine together with radiotherapy was proved to be effective in soft tissue sarcomas (STS). Because Razoxane leads to a redifferentiation of pathological tumor blood vessels, it was of particular interest to study the influence of this drug combination in vascular soft tissue sarcomas. Methods and Materials This open multicenter Phase II study was performed by the Austrian Society of Radiooncology. Among 13 evaluable patients (10 angiosarcomas and 3 hemangio-pericytomas), 9 had unresectable measurable disease, 3 showed microscopic residuals, and 1 had a resection with clear margins. They received a basic treatment with Razoxane and vindesine supported by radiation therapy. Outcome measures were objective response rates, survival time, and the incidence of distant metastases. Results In nine patients with measurable vascular soft tissue sarcomas (eight angiosarcomas and one hemangiopericytoma), 6 complete remissions, 2 partial remissions, and 1 minor remission were achieved, corresponding to a major response rate of 89%. A maintenance therapy with Razoxane and vindesine of 1 year or longer led to a suppression of distant metastases. The median survival time from the start of the treatment is 23+ months (range, 3–120+) for 12 patients with macroscopic and microscopic residual disease. The progression-free survival at 6 months was 75%. The combined treatment was associated with a low general toxicity, but attention must be given to increased normal tissue reactions. Conclusions This trimodal treatment leads to excellent response rates, and it suppresses distant metastases when given as maintenance therapy.
-
Combined vindesine and Razoxane shows antimetastatic activity in advanced soft tissue sarcomas
Clinical & Experimental Metastasis, 2008Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Schmid, Christoph H. SaelyAbstract:Background Razoxane and vindesine were shown to suppress distant metastasis in animal systems. Both drugs affect main steps of the metastatic cascade. Therefore, a pilot study was performed to study the influence of these drugs on the dynamics of metastasis in advanced soft tissue sarcomas (STS). This study was now updated. Methods Twenty-three patients with unresectable ( n = 7) and oligometastatic STS ( n = 16) received a basic treatment with Razoxane and vindesine supported by radiotherapy and occasionally by surgery. Long-term treatment was intended in patients with metastatic disease. The cumulative number of new metastases after 6 and 9 months were determined. Thirty-six patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomized, retrospective controls. The prognostic parameters of the groups were comparable. Results In patients receiving Razoxane and vindesine, the median number of new metastases after 6 months was 0 (range, 0–40) and after 9 months likewise 0 (0–70). The corresponding numbers in the control group were 4.5 (range, 0–40) and 9 (0–>100) ( P
-
Combined vindesine and Razoxane shows antimetastatic activity in advanced soft tissue sarcomas.
Clinical & experimental metastasis, 2007Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Schmid, Christoph SaelyAbstract:Background Razoxane and vindesine were shown to suppress distant metastasis in animal systems. Both drugs affect main steps of the metastatic cascade. Therefore, a pilot study was performed to study the influence of these drugs on the dynamics of metastasis in advanced soft tissue sarcomas (STS). This study was now updated. Methods Twenty-three patients with unresectable (n = 7) and oligometastatic STS (n = 16) received a basic treatment with Razoxane and vindesine supported by radiotherapy and occasionally by surgery. Long-term treatment was intended in patients with metastatic disease. The cumulative number of new metastases after 6 and 9 months were determined. Thirty-six patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomized, retrospective controls. The prognostic parameters of the groups were comparable. Results In patients receiving Razoxane and vindesine, the median number of new metastases after 6 months was 0 (range, 0–40) and after 9 months likewise 0 (0–70). The corresponding numbers in the control group were 4.5 (range, 0–40) and 9 (0–>100) (P < 0.001). The progression-free survival at 6 months was 74% in the study group and 23% in the controls. The median survival time from the occurrence of the first metastasis or the time of unresectability was 20+ months (range, 8–120+) versus 9 months (range, 2–252) (P < 0.001). The combined treatment was associated with a low to moderate toxicity. Conclusions Trimodal treatment with Razoxane, vindesine, and radiotherapy is feasible in patients with unresectable primaries and early metastatic STS. The combination inhibits the development of remote metastases in a majority of the patients and prolongs survival.
-
Razoxane and vindesine in advanced soft tissue sarcomas impact on metastasis survival and radiation response
Anticancer Research, 2007Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Schmid, Christoph SaelyAbstract:Background: The treatment options in advanced soft tissue sarcomas (STS) are limited. In a pilot study, an anti- metastatic and radiosensitizing treatment concept was explored. Patients and Methods: Twenty-one patients with unresectable and/or oligometastatic STS received the drugs Razoxane and vindesine supported by radiotherapy and surgery. Long-term treatment was intended in metastatic disease. Forty-one patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomised controls. The prognostic parameters of the groups were comparable. Results: In the study group, the median number of new metastases after 6 months was 0 (range, 0-40) and after 9 months likewise 0 (0- 70). The corresponding numbers in the control group were 4.5 (range, 0-40) and 9 (0->100) (p<0.001). The progression-free survival at 6 months was 71% in the study group and 23% in the controls, and the median survival time from the occurrence of the first metastasis was 16 months versus 9 months. The rate of major responses under radiotherapy combined with Razoxane and vindesine was 88%, and in the control group 62% (p=0.007). The combined treatment was associated with a low to moderate toxicity. Conclusion: The treatment combination inhibited the development of remote metastases in the majority of patients with STS and prolonged survival to some extent. Available treatment options for unresectable and disseminated soft-tissue sarcomas (STS) are limited. Although some progress has been made in controlling inoperable or gross residual STS by neutron irradiation (1), isolated limb
-
Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer
Strahlentherapie und Onkologie, 2007Co-Authors: Walter Rhomberg, Helmut Eiter, Josef Hammer, Felix Sedlmayer, Dieter Seewald, Barbara SchneiderAbstract:Background and Purpose: In an earlier phase II study, irradiation together with Razoxane was shown to improve local control in recurrent rectal cancer. Therefore, the Austrian Society of Radiooncology (ÖGRO) initiated a randomized controlled trial in 1992 to compare this combined treatment versus radiation therapy alone. Patients and Methods: Between 1992 and 1999, 36 patients with localized recurrences of rectal cancer were randomized to receive radiotherapy without (group A) or with Razoxane (group B). The prognostic variables of the two groups were similar except for a longer median latency period from initial surgery to local recurrence in group A. High-energy photons with daily fractions between 170 and 200 cGy were used. The median total radiation dose was 60 Gy in each group. The patients in group B received a median Razoxane dose of 9.6 g (range, 5–12 g). Main outcome measures were local control, overall survival, and toxicity. Results: The combined treatment with Razoxane increased the local control rate compared to radiotherapy alone (39% vs. 8%; p = 0.05). The median survival time was not different between the groups (20 months each). No patient in arm A but four of 18 patients in arm B survived 5 years. Acute toxic effects were of moderate degree in both groups. There were no substantial differences as to late side effects. Conclusion: Radiotherapy together with Razoxane is superior to radiation treatment alone in recurrent rectal cancer as far as local control is concerned. In some patients, long-term survival was achieved with Razoxane and radiotherapy. Hintergrund und Ziel: Die Kombination von Radiotherapie und Razoxan zeigte in früheren Studien bei Lokalrezidiven von Rektumkarzinomen eine hohe lokale Kontrollrate und verbesserte Überlebenszeiten. Daher wurde 1992 von der Österreichischen Gesellschaft für Radioonkologie (ÖGRO) eine randomisierte Studie begonnen, um diese Kombination mit einer alleinigen Bestrahlung zu vergleichen. Patienten und Methodik: Zwischen 1992 und 1999 wurden 36 Patienten mit inoperablen Rezidiven randomisiert und einer Strahlentherapie allein (Gruppe A) oder in Kombination mit Razoxan (Gruppe B) zugeteilt. Die mediane Strahlendosis betrug in beiden Gruppen 60 Gy, die tägliche Einzeldosis lag zwischen 170 und 200 cGy. Patienten der Gruppe B erhielten eine mediane Razoxandosis von 9,6 g (5–12 g). Die prognostischen Variablen waren in beiden Gruppen ähnlich verteilt mit Ausnahme der Latenzzeit von der Primärdiagnose bis zum Auftreten des Rezidivs (25 Monate vs. 12 Monate in Gruppen A und B). Studienendpunkte waren lokale Kontrolle, Gesamtüberleben und Verträglichkeit. Ergebnisse: Die lokale Tumorkontrolle betrug mit alleiniger Photonentherapie 8%, bei gleichzeitiger Gabe von Razoxan 39% (p = 0,05). Die mediane Überlebenszeit lag in beiden Gruppen bei 20 Monaten. In Gruppe A überlebte kein Patient 5 Jahre, in Gruppe B vier von 18 Patienten. Akute Nebenwirkungen der Grade 1–3 und Strahlenspätreaktionen waren in beiden Gruppen ähnlich verteilt. Schlussfolgerung: Radiotherapie zusammen mit Razoxan ist einer alleinigen Bestrahlung bezüglich lokaler Tumorkontrolle beim inoperablen Rezidiv des Rektumkarzinoms überlegen. Im Kombinationsarm fand sich häufiger ein Langzeitüberleben.
Christoph Saely - One of the best experts on this subject based on the ideXlab platform.
-
Combined vindesine and Razoxane shows antimetastatic activity in advanced soft tissue sarcomas.
Clinical & experimental metastasis, 2007Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Schmid, Christoph SaelyAbstract:Background Razoxane and vindesine were shown to suppress distant metastasis in animal systems. Both drugs affect main steps of the metastatic cascade. Therefore, a pilot study was performed to study the influence of these drugs on the dynamics of metastasis in advanced soft tissue sarcomas (STS). This study was now updated. Methods Twenty-three patients with unresectable (n = 7) and oligometastatic STS (n = 16) received a basic treatment with Razoxane and vindesine supported by radiotherapy and occasionally by surgery. Long-term treatment was intended in patients with metastatic disease. The cumulative number of new metastases after 6 and 9 months were determined. Thirty-six patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomized, retrospective controls. The prognostic parameters of the groups were comparable. Results In patients receiving Razoxane and vindesine, the median number of new metastases after 6 months was 0 (range, 0–40) and after 9 months likewise 0 (0–70). The corresponding numbers in the control group were 4.5 (range, 0–40) and 9 (0–>100) (P < 0.001). The progression-free survival at 6 months was 74% in the study group and 23% in the controls. The median survival time from the occurrence of the first metastasis or the time of unresectability was 20+ months (range, 8–120+) versus 9 months (range, 2–252) (P < 0.001). The combined treatment was associated with a low to moderate toxicity. Conclusions Trimodal treatment with Razoxane, vindesine, and radiotherapy is feasible in patients with unresectable primaries and early metastatic STS. The combination inhibits the development of remote metastases in a majority of the patients and prolongs survival.
-
Razoxane and vindesine in advanced soft tissue sarcomas impact on metastasis survival and radiation response
Anticancer Research, 2007Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Schmid, Christoph SaelyAbstract:Background: The treatment options in advanced soft tissue sarcomas (STS) are limited. In a pilot study, an anti- metastatic and radiosensitizing treatment concept was explored. Patients and Methods: Twenty-one patients with unresectable and/or oligometastatic STS received the drugs Razoxane and vindesine supported by radiotherapy and surgery. Long-term treatment was intended in metastatic disease. Forty-one patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomised controls. The prognostic parameters of the groups were comparable. Results: In the study group, the median number of new metastases after 6 months was 0 (range, 0-40) and after 9 months likewise 0 (0- 70). The corresponding numbers in the control group were 4.5 (range, 0-40) and 9 (0->100) (p<0.001). The progression-free survival at 6 months was 71% in the study group and 23% in the controls, and the median survival time from the occurrence of the first metastasis was 16 months versus 9 months. The rate of major responses under radiotherapy combined with Razoxane and vindesine was 88%, and in the control group 62% (p=0.007). The combined treatment was associated with a low to moderate toxicity. Conclusion: The treatment combination inhibited the development of remote metastases in the majority of patients with STS and prolonged survival to some extent. Available treatment options for unresectable and disseminated soft-tissue sarcomas (STS) are limited. Although some progress has been made in controlling inoperable or gross residual STS by neutron irradiation (1), isolated limb
-
Razoxane and vindesine in advanced soft tissue sarcomas: impact on metastasis, survival and radiation response.
Anticancer research, 2007Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Schmid, Christoph SaelyAbstract:Background: The treatment options in advanced soft tissue sarcomas (STS) are limited. In a pilot study, an anti- metastatic and radiosensitizing treatment concept was explored. Patients and Methods: Twenty-one patients with unresectable and/or oligometastatic STS received the drugs Razoxane and vindesine supported by radiotherapy and surgery. Long-term treatment was intended in metastatic disease. Forty-one patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomised controls. The prognostic parameters of the groups were comparable. Results: In the study group, the median number of new metastases after 6 months was 0 (range, 0-40) and after 9 months likewise 0 (0- 70). The corresponding numbers in the control group were 4.5 (range, 0-40) and 9 (0->100) (p
-
Combined Razoxane and radiotherapy for melanoma brain metastases. a retrospective analysis.
Journal of neuro-oncology, 2005Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Boehler, Christoph Saely, Robert StrohalAbstract:We retrospectively compared the efficacy of Razoxane and radiotherapy with radiotherapy alone or in combination with a non-Razoxane based medication in patients with melanoma brain metastases. From 19 assessable patients receiving whole brain irradiation with or without a boost (mean total dose 40.5 Gy) for measurable brain metastases, 8 patients underwent an additional Razoxane therapy with 125 mg per os twice daily started 5 days before radiotherapy and given throughout the whole radiation period. The median Razoxane dose was 6.25 g (range 3.2–8.0 g). Endpoints included radiation response rates, median survival time and 1-year survival rates. To generate reliable prognostic parameters for this non-randomized study population, the Score Index for Stereotactic Radiosurgery and the Radiation Therapy Oncology Group Recursive Partitioning Analysis score were applied. Radiotherapy with Razoxane led to higher response rates (62% vs. 27%) and a lower percentage of progressive disease (12.5% vs. 36%) if compared with radiotherapy alone or with a non-Razoxane based medication. This combination was associated with a longer median survival (5 months vs. 2.2 months; P=0.052) and a 1-year survival rate of 37.5% vs. 0% (P=0.027). Both treatment groups belonged to similar prognosis subsets. The treatment was well tolerated. Taken together our data support the therapeutic concept of a combined Razoxane radiation therapy in melanoma patients with brain metastases. The favorable treatment effects are probably due to the radiosensitizing and the cytorallentaric mode of action of Razoxane. Since the patient numbers are low, confirmatory studies are certainly necessary.
Franz Schmid - One of the best experts on this subject based on the ideXlab platform.
-
Combined vindesine and Razoxane shows antimetastatic activity in advanced soft tissue sarcomas
Clinical & Experimental Metastasis, 2008Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Schmid, Christoph H. SaelyAbstract:Background Razoxane and vindesine were shown to suppress distant metastasis in animal systems. Both drugs affect main steps of the metastatic cascade. Therefore, a pilot study was performed to study the influence of these drugs on the dynamics of metastasis in advanced soft tissue sarcomas (STS). This study was now updated. Methods Twenty-three patients with unresectable ( n = 7) and oligometastatic STS ( n = 16) received a basic treatment with Razoxane and vindesine supported by radiotherapy and occasionally by surgery. Long-term treatment was intended in patients with metastatic disease. The cumulative number of new metastases after 6 and 9 months were determined. Thirty-six patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomized, retrospective controls. The prognostic parameters of the groups were comparable. Results In patients receiving Razoxane and vindesine, the median number of new metastases after 6 months was 0 (range, 0–40) and after 9 months likewise 0 (0–70). The corresponding numbers in the control group were 4.5 (range, 0–40) and 9 (0–>100) ( P
-
Combined vindesine and Razoxane shows antimetastatic activity in advanced soft tissue sarcomas.
Clinical & experimental metastasis, 2007Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Schmid, Christoph SaelyAbstract:Background Razoxane and vindesine were shown to suppress distant metastasis in animal systems. Both drugs affect main steps of the metastatic cascade. Therefore, a pilot study was performed to study the influence of these drugs on the dynamics of metastasis in advanced soft tissue sarcomas (STS). This study was now updated. Methods Twenty-three patients with unresectable (n = 7) and oligometastatic STS (n = 16) received a basic treatment with Razoxane and vindesine supported by radiotherapy and occasionally by surgery. Long-term treatment was intended in patients with metastatic disease. The cumulative number of new metastases after 6 and 9 months were determined. Thirty-six patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomized, retrospective controls. The prognostic parameters of the groups were comparable. Results In patients receiving Razoxane and vindesine, the median number of new metastases after 6 months was 0 (range, 0–40) and after 9 months likewise 0 (0–70). The corresponding numbers in the control group were 4.5 (range, 0–40) and 9 (0–>100) (P < 0.001). The progression-free survival at 6 months was 74% in the study group and 23% in the controls. The median survival time from the occurrence of the first metastasis or the time of unresectability was 20+ months (range, 8–120+) versus 9 months (range, 2–252) (P < 0.001). The combined treatment was associated with a low to moderate toxicity. Conclusions Trimodal treatment with Razoxane, vindesine, and radiotherapy is feasible in patients with unresectable primaries and early metastatic STS. The combination inhibits the development of remote metastases in a majority of the patients and prolongs survival.
-
Razoxane and vindesine in advanced soft tissue sarcomas impact on metastasis survival and radiation response
Anticancer Research, 2007Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Schmid, Christoph SaelyAbstract:Background: The treatment options in advanced soft tissue sarcomas (STS) are limited. In a pilot study, an anti- metastatic and radiosensitizing treatment concept was explored. Patients and Methods: Twenty-one patients with unresectable and/or oligometastatic STS received the drugs Razoxane and vindesine supported by radiotherapy and surgery. Long-term treatment was intended in metastatic disease. Forty-one patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomised controls. The prognostic parameters of the groups were comparable. Results: In the study group, the median number of new metastases after 6 months was 0 (range, 0-40) and after 9 months likewise 0 (0- 70). The corresponding numbers in the control group were 4.5 (range, 0-40) and 9 (0->100) (p<0.001). The progression-free survival at 6 months was 71% in the study group and 23% in the controls, and the median survival time from the occurrence of the first metastasis was 16 months versus 9 months. The rate of major responses under radiotherapy combined with Razoxane and vindesine was 88%, and in the control group 62% (p=0.007). The combined treatment was associated with a low to moderate toxicity. Conclusion: The treatment combination inhibited the development of remote metastases in the majority of patients with STS and prolonged survival to some extent. Available treatment options for unresectable and disseminated soft-tissue sarcomas (STS) are limited. Although some progress has been made in controlling inoperable or gross residual STS by neutron irradiation (1), isolated limb
-
Razoxane and vindesine in advanced soft tissue sarcomas: impact on metastasis, survival and radiation response.
Anticancer research, 2007Co-Authors: Walter Rhomberg, Helmut Eiter, Franz Schmid, Christoph SaelyAbstract:Background: The treatment options in advanced soft tissue sarcomas (STS) are limited. In a pilot study, an anti- metastatic and radiosensitizing treatment concept was explored. Patients and Methods: Twenty-one patients with unresectable and/or oligometastatic STS received the drugs Razoxane and vindesine supported by radiotherapy and surgery. Long-term treatment was intended in metastatic disease. Forty-one patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomised controls. The prognostic parameters of the groups were comparable. Results: In the study group, the median number of new metastases after 6 months was 0 (range, 0-40) and after 9 months likewise 0 (0- 70). The corresponding numbers in the control group were 4.5 (range, 0-40) and 9 (0->100) (p
Richard Potter - One of the best experts on this subject based on the ideXlab platform.
-
treatment of vascular soft tissue sarcomas with Razoxane vindesine and radiation
International Journal of Radiation Oncology Biology Physics, 2009Co-Authors: Walter Rhomberg, Helmut Eiter, Anna Wink, Boris Pokrajac, B Pakisch, Angela Ginestet, Peter Lukas, ACHIM HACKL, Richard PotterAbstract:Purpose In previous studies, Razoxane and vindesine together with radiotherapy was proved to be effective in soft tissue sarcomas (STS). Because Razoxane leads to a redifferentiation of pathological tumor blood vessels, it was of particular interest to study the influence of this drug combination in vascular soft tissue sarcomas. Methods and Materials This open multicenter Phase II study was performed by the Austrian Society of Radiooncology. Among 13 evaluable patients (10 angiosarcomas and 3 hemangio-pericytomas), 9 had unresectable measurable disease, 3 showed microscopic residuals, and 1 had a resection with clear margins. They received a basic treatment with Razoxane and vindesine supported by radiation therapy. Outcome measures were objective response rates, survival time, and the incidence of distant metastases. Results In nine patients with measurable vascular soft tissue sarcomas (eight angiosarcomas and one hemangiopericytoma), 6 complete remissions, 2 partial remissions, and 1 minor remission were achieved, corresponding to a major response rate of 89%. A maintenance therapy with Razoxane and vindesine of 1 year or longer led to a suppression of distant metastases. The median survival time from the start of the treatment is 23+ months (range, 3–120+) for 12 patients with macroscopic and microscopic residual disease. The progression-free survival at 6 months was 75%. The combined treatment was associated with a low general toxicity, but attention must be given to increased normal tissue reactions. Conclusions This trimodal treatment leads to excellent response rates, and it suppresses distant metastases when given as maintenance therapy.
